Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries

BACKGROUND: Bone metastases (BMs) are common in patients with breast cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), like zoledronic acid and denosumab, reduce the incidence of SREs and de...

Descripción completa

Detalles Bibliográficos
Autores principales: von Moos, Roger, Body, Jean-Jacques, Rider, Alex, de Courcy, Jonathan, Bhowmik, Debajyoti, Gatta, Francesca, Hechmati, Guy, Qian, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993954/
https://www.ncbi.nlm.nih.gov/pubmed/29892519
http://dx.doi.org/10.1016/j.jbo.2017.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993954/
https://www.ncbi.nlm.nih.gov/pubmed/29892519
http://dx.doi.org/10.1016/j.jbo.2017.11.004

Ejemplares similares